Acidi grassi Omega-3 per Telogen effluvium
B Evidenze Almeno un trial randomizzato lo supporta, con risultati per lo più coerenti.Basato su 11 studi con 317 partecipanti totali. 8/11 studi mostrano effetti positivi.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'haircited.com';
const params = 'ingredient\u003Domega\u002D3\u0026condition\u003Dtelogen\u002Deffluvium';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
In sintesi
Moderate evidence suggests that omega-3 fatty acids may help support hair recovery in telogen effluvium, though the research base is limited and they are usually studied alongside other nutrients.
- 8 out of 11 studies show positive effects, but total sample size is small (317 participants)
- Often studied as part of multi-nutrient supplement formulations
- No large-scale RCTs specifically for omega-3 and telogen effluvium
- May support recovery through anti-inflammatory and nutritional mechanisms
Key Study Findings
review
Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.
Dose: Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5
vs: Placebo
Effetto: Comparable efficacy to topical minoxidil; hypertrichosis 24%, shedding 16-22%, peripheral edema 2%
None
narrative review
Herbal Remedies for Hair Loss: A Review of Efficacy and Safety.
Dose: varies by remedy and study
vs: Placebo
Effetto: None
None
scoping_review
n=16
A Scoping Review of Exosome Delivery Applications in Hair Loss.
Dose: variable; exosomes predominantly from mesenchymal stem cells (MSCs)
vs: Placebo
Effetto: None
None
review
The Use of Light-Based Therapies in the Treatment of Alopecia.
Dose: Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri
vs: Placebo
Effetto: LLLT improves hair density in AGA; potential to prolong anagen phase in telogen effluvium; may promo
None
Cohort
n=200
Open-label
Iron Supplementation May Improve the Patient's Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life …
Dose: high dose elemental iron (dose unspecified)
vs: Placebo
Effetto: Patients with baseline ferritin ≥50 ng/ml mostly 'very satisfied'; patients with ferritin <50 ng/ml
None
clinical trial (open-label)
Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with …
Dose: None
vs: Placebo
Effetto: None
None
Key Statistics
11
Studi
317
Partecipanti
↑
Positive
B
Grado
Referenced Papers
American journal of …
2026
1 citazioni
Cureus
2025
7 citazioni
Skin appendage disorders
2025
7 citazioni
Journal of cosmetic …
2025
Indian journal of …
2024
4 citazioni
Journal of cosmetic …
2023
6 citazioni
Journal of cosmetic …
2022
30 citazioni
NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India.
Observational
Journal of cosmetic …
2019
25 citazioni
Acta dermatovenerologica Croatica …
2016
6 citazioni
Georgian medical news
2007
Therapeutische Umschau. Revue …
2002
4 citazioni
Dermatologic clinics
1993
38 citazioni
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Dosaggi di uso comune
- general:
- 250-500 mg EPA+DHA/day
- hairloss:
- 1,000-2,000 mg/day
Limite massimo: 3,000 mg/day EPA+DHA
Dosaggi studiati nella ricerca
| Dosaggio | Durata | Effetto | N |
|---|---|---|---|
| Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 | -- | Positive | -- |
| varies by remedy and study | -- | Positive | -- |
| variable; exosomes predominantly from mesenchymal stem cells (MSCs) | -- | Positive | 16 |
| Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri | -- | Positive | -- |
| high dose elemental iron (dose unspecified) | -- | Positive | 200 |
| None | -- | Positive | -- |
| None | -- | Neutral | 100 |
| psychiatric and dermatological management | -- | Neutral | 1 |
Momento migliore per l'assunzione: With meals containing fat for optimal absorption; split doses if over 1,000 mg
Safety & Side Effects
Effetti collaterali segnalati
- ⚠ Fishy aftertaste or burping
- ⚠ Mild gastrointestinal upset (nausea, diarrhea)
- ⚠ Possible increased bleeding time at high doses
- ⚠ Unpleasant body odor at very high doses
Interazioni note
- ● Anticoagulants (warfarin) and antiplatelet drugs (may increase bleeding risk)
- ● Blood pressure medications (additive hypotensive effect)
- ● Orlistat (reduces omega-3 absorption)
Livello di assunzione massimo tollerabile: 3,000 mg/day EPA+DHA
Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.
Frequently Asked Questions
Does Acidi grassi Omega-3 help with Telogen effluvium?
Based on 11 studies with 317 participants, there is moderate evidence from clinical studies that Acidi grassi Omega-3 may support Telogen effluvium management. Our evidence grade is B (Good Evidence).
How much Acidi grassi Omega-3 should I take for Telogen effluvium?
Studies have used various dosages. A commonly studied range is 250-500 mg EPA+DHA/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Acidi grassi Omega-3?
Reported side effects may include Fishy aftertaste or burping, Mild gastrointestinal upset (nausea, diarrhea), Possible increased bleeding time at high doses, Unpleasant body odor at very high doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Acidi grassi Omega-3 and Telogen effluvium?
We rate the evidence as Grade B (Good Evidence). This rating is based on 11 peer-reviewed studies with 317 total participants. The overall direction of effect is positive.
Related Evidence
Altri ingredienti per Telogen effluvium
Acidi grassi Omega-3 per altre condizioni
References
- [1] Michael M Ong et al.. Am J Clin Dermatol. 2026. Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations. doi:10.1007/s40257-025-00990-4 PubMed
- [2] Sarah Schaffer et al.. Cureus. 2025. A Scoping Review of Exosome Delivery Applications in Hair Loss. doi:10.7759/cureus.81152 PubMed
- [3] Azhar Ahmed et al.. Skin Appendage Disord. 2025. Herbal Remedies for Hair Loss: A Review of Efficacy and Safety. doi:10.1159/000542876 PubMed
- [4] Robert J Vanaria et al.. J Cosmet Dermatol. 2025. The Use of Light-Based Therapies in the Treatment of Alopecia. doi:10.1111/jocd.70434 PubMed
- [5] Boutros Soutou et al.. Indian J Dermatol. 2024. Iron Supplementation May Improve the Patient's Level of Satisfaction in Not-Low-Ferritin Telogen Effluvium: A Real-Life Observational Study. doi:10.4103/ijd.ijd_744_22 PubMed
- [6] S Cedirian et al.. J Cosmet Dermatol. 2023. Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic … doi:10.1111/jocd.15873 PubMed
- [7] Kabir Sardana et al.. J Cosmet Dermatol. 2022. Role of nutritional supplements in selected dermatological disorders: A review. doi:10.1111/jocd.14436 PubMed
- [8] Kavita Poonia et al.. J Cosmet Dermatol. 2019. NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India. doi:10.1111/jocd.12559 PubMed
- [9] Jana Zímová et al.. Acta Dermatovenerol Croat. 2016. Trichotillomania: Bizzare Patern of Hair Loss at 11-Year-old Girl. PubMed
- [10] N V Tsiskarishvili et al.. Georgian Med News. 2007. [Effectiveness of the treatment plan for androgenetic alopecia]. PubMed
- [11] R M Trüeb. Ther Umsch. 2002. [Diffuse hair loss in women]. doi:10.1024/0040-5930.59.5.217 PubMed
- [12] D H Rushton. Dermatol Clin. 1993. Management of hair loss in women. PubMed
Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.